Understanding the cellular mode of action of vernakalant using a computational model: answers and new questions
Vernakalant is a new antiarrhythmic agent for the treatment of atrial fibrillation. While it has proven to be effective in a large share of patients in clinical studies, its underlying mode of action is not fully understood. In this work, we aim to link experimental data from the subcellular, tissue...
Main Authors: | Loewe Axel, Xu Yan, Scholz Eberhard P., Dössel Olaf, Seemann Gunnar |
---|---|
Format: | Article |
Language: | English |
Published: |
De Gruyter
2015-09-01
|
Series: | Current Directions in Biomedical Engineering |
Subjects: | |
Online Access: | http://www.degruyter.com/view/j/cdbme.2015.1.issue-1/cdbme-2015-0101/cdbme-2015-0101.xml?format=INT |
Similar Items
-
Vernakalant Use in Cardioversion of Recent Onset Atrial Fibrillation: A Case Report
by: Niković Vuk, et al.
Published: (2018-09-01) -
by: Antoine Kossaify
Published: (2019-07-01) -
Options for antiarrhythmic therapy after surgical treatment of the atrial fibrillation
by: V. V Bazylev, et al.
Published: (2015-12-01) -
Radical-mediated dehydrative preparation of cyclic imides using (NH4)2S2O8–DMSO: application to the synthesis of vernakalant
by: Dnyaneshwar N. Garad, et al.
Published: (2015-06-01) -
Quality of life after surgical treatment of atrial fibrillation
by: V. V Bazylev, et al.
Published: (2017-09-01)